📊 GOVX Key Takeaways
Is GOVX a Good Investment? Thesis Analysis
GeoVax Labs is a pre-commercial stage pharmaceutical company with unsustainable cash burn of $16.5M annually against minimal revenue of $2.5M and only $5M in cash reserves, implying critical liquidity stress within 3-4 months. Massive operating losses (-$17.2M), negative profitability margins exceeding -684%, and severe shareholder value destruction indicate severe financial distress requiring imminent dilutive financing or strategic intervention.
GeoVax generates minimal revenue and posts extremely negative margins and returns, with operating cash burn far exceeding its cash balance. Despite being debt-free with a decent current ratio, the business appears reliant on external financing and uncertain pipeline progress, leaving fundamentals weak.
Why Buy GOVX? Key Strengths
- Zero debt burden with Debt/Equity ratio of 0.00x reduces financial leverage risk
- Strong current ratio of 3.57x demonstrates adequate short-term liquidity relative to current liabilities
- Cash reserves of $5.0M provide near-term operational runway
- Debt-free balance sheet
- Solid current/quick ratio supporting near-term liquidity
- Asset-light with minimal capex requirements
GOVX Investment Risks to Consider
- Critical cash runway of approximately 3-4 months at current burn rate of $16.5M annually with only $5M cash
- Revenue of $2.5M vastly insufficient to cover $17.2M operating losses, indicating pre-commercial development stage with execution risk
- Negative profitability metrics (-684.8% net margin, -690.9% operating margin, -347.4% ROE) indicate severe ongoing shareholder value destruction
- Pre-commercial pharmaceutical development status creates high regulatory approval and clinical trial risk
- Likely need for imminent dilutive equity financing or partnerships to survive beyond 2026
- Severe operating losses and deeply negative free cash flow
- Short cash runway and high dilution/going-concern risk
- Execution and regulatory risk with volatile, non-recurring revenue sources
Key Metrics to Watch
- Monthly cash burn rate and cash runway extension milestones
- Revenue trajectory and achievement of clinical development milestones
- Announcement of capital raises, partnerships, or acquisition activity
- Quarterly operating cash burn and cash runway
- TTM revenue growth from partnerships/grants/licensing
GOVX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.57x current ratio provides a solid financial cushion.
GOVX Profitability Ratios
GOVX vs Healthcare Sector
How GeoVax Labs, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GOVX Overvalued or Undervalued?
Based on fundamental analysis, GeoVax Labs, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GOVX Balance Sheet & Liquidity
GOVX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: GeoVax Labs, Inc.'s revenue has grown significantly by 117% over the 5-year period, indicating strong business expansion. The most recent EPS of $-14.29 indicates the company is currently unprofitable.
GOVX Growth Metrics (YoY)
GOVX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$5.1M | $-0.31 |
| Q2 2025 | $300.7K | -$5.1M | $-0.35 |
| Q1 2025 | N/A | -$5.4M | $-0.45 |
| Q3 2024 | N/A | -$4.0M | $-0.91 |
| Q2 2024 | N/A | -$4.0M | $-1.99 |
| Q3 2023 | N/A | -$2.2M | $-0.17 |
| Q2 2023 | N/A | -$2.2M | $-0.18 |
| Q1 2023 | N/A | -$2.4M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GOVX Capital Allocation
GOVX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for GeoVax Labs, Inc. (CIK: 0000832489)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GOVX
What is the AI rating for GOVX?
GeoVax Labs, Inc. (GOVX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GOVX's key strengths?
Claude: Zero debt burden with Debt/Equity ratio of 0.00x reduces financial leverage risk. Strong current ratio of 3.57x demonstrates adequate short-term liquidity relative to current liabilities. ChatGPT: Debt-free balance sheet. Solid current/quick ratio supporting near-term liquidity.
What are the risks of investing in GOVX?
Claude: Critical cash runway of approximately 3-4 months at current burn rate of $16.5M annually with only $5M cash. Revenue of $2.5M vastly insufficient to cover $17.2M operating losses, indicating pre-commercial development stage with execution risk. ChatGPT: Severe operating losses and deeply negative free cash flow. Short cash runway and high dilution/going-concern risk.
What is GOVX's revenue and growth?
GeoVax Labs, Inc. reported revenue of $2.5M.
Does GOVX pay dividends?
GeoVax Labs, Inc. does not currently pay dividends.
Where can I find GOVX SEC filings?
Official SEC filings for GeoVax Labs, Inc. (CIK: 0000832489) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GOVX's EPS?
GeoVax Labs, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GOVX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, GeoVax Labs, Inc. has a STRONG SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GOVX stock overvalued or undervalued?
Valuation metrics for GOVX: ROE of -347.4% (sector avg: 15%), net margin of -684.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GOVX stock in 2026?
Our dual AI analysis gives GeoVax Labs, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GOVX's free cash flow?
GeoVax Labs, Inc.'s operating cash flow is $-16.5M, with capital expenditures of $27.6K. FCF margin is -664.5%.
How does GOVX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -684.8% (avg: 12%), ROE -347.4% (avg: 15%), current ratio 3.57 (avg: 2).